Rachel E.Page

Associate

シカゴ + 1.312.269.4092

Connect:

共有

Rachel Page focuses her practice on the representation of health care and life sciences companies. She represents hospitals, health systems, physician group practices, hospice providers, pharmaceutical and medical device manufacturers, and emerging and established companies in the digital health and health technology sectors.

Rachel counsels clients on regulatory and compliance issues, including federal and state anti-kickback statutes, reimbursement, the Physician Payments Sunshine Act (Open Payments), compliance program development and assessment, clinical research and U.S. Food & Drug Administration (FDA) regulations, licensure, direct-to-consumer telemedicine and telehealth, and state corporate practice of medicine doctrines. She also defends health care and life sciences clients in investigations and litigation relating to the False Claims Act, the federal Anti-Kickback Statute, and the Stark Law brought by federal agencies and qui tam whistleblowers and assists in conducting internal investigations and developing repayment strategies.

She handles transactional matters for clients, advising on structural considerations, diligence, and risk mitigation strategies for a variety of transactions, including hospital, hospice, home health, and physician practice acquisitions; private equity investments; and corporate and commercial arrangements in the life sciences industry.

Prior to attending law school, Rachel worked in the legal and compliance department for a regional health insurance company during the implementation of the Affordable Care Act. She is a member of the American Health Lawyers Association and the Illinois Association of Healthcare Attorneys. In 2022, Rachel received the Law360 Rising Star Award in Health Care, which is awarded to the "top attorneys under 40" whose legal accomplishments transcend their age.

担当案件

  • Riverside sells Red Nucleus to Thomas H. Lee PartnersJones Day represented The Riverside Company in its sale of Red Nucleus, an industry-leading integrated provider of learning and development, medical communications, market access, and R&D and clinical solutions to the life sciences industry globally, to Thomas H. Lee Partners.
  • Reneo Pharmaceuticals announces reverse merger with OnKureJones Day represented Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) in an all-stock reverse merger between Reneo and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company valued at $170 million that is focused on the development of novel precision medicines in oncology.
  • Accelmed Partners acquires Bioventus Advanced Rehabilitation businessJones Day is advising Accelmed Partners in its acquisition of Bioventus Inc.'s Advanced Rehabilitation business.
  • Atlantic Health System acquires Saint Peter’s Healthcare SystemJones Day is advising Atlantic Health System in the acquisition of Saint Peter's Healthcare System.
  • Direct lender provides $87 million senior secured credit facility to large private equity-backed provider of medical supplies to companies in commercial cruise and shipping industriesJones Day advised a direct lender, as administrative agent, collateral agent, sole lead arranger, and lender, in connection with a $87 million senior secured credit facility provided to a large private equity sponsored company that provides medical supplies to companies in the commercial cruise and shipping industries.
  • Sumitomo acquires assets and rights related to lefamulin from NabrivaJones Day advised Sumitomo Pharma Co., Ltd. in the acquisition of assets from Nabriva Therapeutics plc and various wholly-owned subsidiaries. This acquisition includes assets from the U.S., Ireland, and Austria in support of the development, manufacture, marketing and commercialization of lefamulin in the People’s Republic of China, Hong Kong, Macau and Taiwan.
  • Astellas acquires Iveric bioJones Day advised Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.
  • Medical device company obtains non-prosecution agreement and favorable False Claims Act settlement with SDNYJones Day represented a medical device manufacturer in a criminal and False Claims Act investigation conducted by the Southern District of New York regarding allegations of health care and wire fraud.
  • Organon makes strategic investment in Claria MedicalJones Day advised Organon in the strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.
  • Cardinal Health acquires the Bendcare CPO-GPO entity and makes a minority investment in the Bendcare MSOJones Day advised Cardinal Health, Inc. in the acquisition of the Bendcare group purchasing organization (CPO-GPO) entity and a minority investment in the Bendcare management services organization (MSO).
  • City of Hope acquires Cancer Treatment Centers of AmericaJones Day advised City of Hope, a world-renowned, National Cancer Institute (NCI)-designated comprehensive cancer research and treatment organization, in connection with its acquisition of Cancer Treatment Centers of America, a network of oncology hospitals and outpatient care centers across the United States.
  • JourneyCare acquired by Addus HomeCareJones Day advised JourneyCare, Inc. in the $85 million sale of the Company to Addus HomeCare Corporation.
  • Dorilton Capital acquires Homestead HospiceJones Day represented Dorilton Capital in the acquisition by portfolio company Traditions Health, LLC, a national hospice and home health provider, of Roswell, Georgia, based Homestead Hospice, a multi-state provider of hospice services.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • AbbVie acquires Mitokinin, Inc.Jones Day advised AbbVie Inc. in its exclusive right to acquire Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, following completion of IND enabling studies on Mitokinin's lead PINK1 compound.
  • Digital health companies, specialty hospitals, and health systems maintain compliance with multistate requirements through 50-state surveyJones Day is representing digital health companies, specialty hospitals, and health systems in maintaining compliance with multistate requirements through a regularly updated, extensive 50-state survey on state laws and regulations applicable to telehealth activities of physicians and other health care professionals including licensing, establishing patient relationships, provider-to-provider consulting, supervision and delegation among providers, and prescribing and treatment standards.
  • ProMedica Health System acquires Toledo Orthopaedic SurgeonsJones Day advised ProMedica Central Physicians, an affiliate of ProMedica Health System, Inc., in its acquisition of Toledo Orthopaedic Surgeons, an orthopedic surgery and sports medicine practice, and employment of its physicians.
  • Riverside portfolio company acquires CordicoJones Day represented The Riverside Company in connection with the acquisition and financing by portfolio company Lexipol, LLC of Cordico, a provider of purpose-built, mobile health and wellness applications that deliver high-quality wellness tools, resources and assessments to public safety customers including law enforcement, fire, EMS, corrections, and more.
  • STERIS acquires Key Surgical for approximately $850 millionJones Day advised STERIS plc (NYSE: STE) in the $850 million acquisition of Key Surgical, a leading global provider of sterile processing, operating room, and endoscopy products, and a portfolio company of Water Street Healthcare Partners, LLC.
  • Telehealth provider obtains dismissal of complaint before state regulatory boardJones Day represented a telehealth provider in responding to a complaint filed with a state regulatory board.
    •

    November 2024 Alert

    Inaugural Meeting for FDA's Digital Health Advisory Committee to Focus on GenAI-enabled Medical Devices

    June 2024 White Paper

    2023 False Claims Act Enforcement in Health Care and Life Sciences, Part III

    April 2024 White Paper

    2023 False Claims Act Enforcement in Health Care and Life Sciences, Part II

    March 2024 White Paper

    2023 False Claims Act Enforcement in Health Care and Life Sciences, Part I

    March 2024 Alert

    Federal Agencies Launch Joint Inquiry Into Private Investment in Health Care

    November 2023 Newsletters

    Vital Signs: Digital Health Law Update | Fall 2023

    September 2023 Newsletters

    Vital Signs Digital Health Law Update | Summer 2023

    September 2023 ニュースレター

    Vital Signs: デジタルヘルス法アップデート | 2023年夏

    May 2023 Newsletters

    Vital Signs Digital Health Law Update | Spring 2023

    July 2022 Newsletters

    Vital Signs: Digital Health Law Update | July 2022
    インサイト一覧

    送信する前の注意事項：

    www.jonesday.comに掲載されている情報は、一般的な使用を目的としており、法的アドバイスを目的としたものではありません。このEmailを送信することにより、弁護士を含む専門家・依頼者の関係を構築することを意図するものではなく、このEmailの受領はそのような関係を構築するものではありません。当事務所に送信されたいかなる情報も、業務委託契約を結ばない限り、弁護士等が依頼者に対して守秘義務を負う機密事項として取り扱われることはありません。このEmailの送信者は以上の注意事項の内容を読み、理解したものと判断します。